Taneptacogin alfa

Drug Profile

Taneptacogin alfa

Alternative Names: Active Site Inactivated Seven; Active Site Inhibited Seven; ASIS; FFR-FVIIa; FFR-VIIa

Latest Information Update: 07 Sep 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class
  • Mechanism of Action Factor VIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Coronary artery restenosis; Thrombosis; Vascular restenosis

Most Recent Events

  • 07 Sep 2004 Discontinued - Phase-II for Adult respiratory distress syndrome (unspecified route)
  • 06 Feb 2003 Phase-II clinical trials in Adult respiratory distress syndrome (unspecified route)
  • 21 Sep 2000 Discontinued-II for Coronary artery restenosis in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top